Oyster Point Pharma Statistics
Share Statistics
Oyster Point Pharma has 0
shares outstanding. The number of shares has increased by 2.66%
in one year.
| Shares Outstanding | n/a |
| Shares Change (YoY) | 2.66% |
| Shares Change (QoQ) | 1.93% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -4.55 and the forward
PE ratio is null.
Oyster Point Pharma's PEG ratio is
-0.12.
| PE Ratio | -4.55 |
| Forward PE | n/a |
| PS Ratio | 19.38 |
| Forward PS | n/a |
| PB Ratio | 4.78 |
| P/FCF Ratio | -5.23 |
| PEG Ratio | -0.12 |
Financial Ratio HistoryEnterprise Valuation
Oyster Point Pharma has an Enterprise Value (EV) of 374.81M.
| EV / Sales | 15.27 |
| EV / EBITDA | -3.87 |
| EV / EBIT | -4.19 |
| EV / FCF | -4.13 |
Financial Position
The company has a current ratio of 7.47,
with a Debt / Equity ratio of 0.93.
| Current Ratio | 7.47 |
| Quick Ratio | 7.26 |
| Debt / Equity | 0.93 |
| Debt / EBITDA | -0.96 |
| Debt / FCF | -1.02 |
| Interest Coverage | -25.96 |
Financial Efficiency
Return on Equity is -104.88% and Return on Invested Capital is -52.28%.
| Return on Equity | -104.88% |
| Return on Assets | -46.89% |
| Return on Invested Capital | -52.28% |
| Revenue Per Employee | $80,986.8 |
| Profits Per Employee | $-344,531.35 |
| Employee Count | 303 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 0.25 |
Taxes
| Income Tax | 3.73M |
| Effective Tax Rate | -3.71% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 0, so Oyster Point Pharma's
price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 10.42 |
| 200-Day Moving Average | 7.48 |
| Relative Strength Index (RSI) | 65.49 |
| Average Volume (20 Days) | 417,562 |
Income Statement
In the last 12 months, Oyster Point Pharma had revenue of 24.54M
and earned -104.39M
in profits. Earnings per share was -4.01.
| Revenue | 24.54M |
| Gross Profit | 23.01M |
| Operating Income | -96.92M |
| Net Income | -104.39M |
| EBITDA | -96.78M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -4.01 |
Full Income StatementBalance Sheet
The company has 193.37M in cash and 92.73M in
debt, giving a net cash position of 100.64M.
| Cash & Cash Equivalents | 193.37M |
| Total Debt | 92.73M |
| Net Cash | 100.64M |
| Retained Earnings | -255.41M |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -89.37M
and capital expenditures -1.49M, giving a free cash flow of -90.86M.
| Operating Cash Flow | -89.37M |
| Capital Expenditures | -1.49M |
| Free Cash Flow | -90.86M |
| FCF Per Share | -3.49 |
Full Cash Flow StatementMargins
Gross margin is 93.79%, with operating and profit margins of -394.98% and -425.42%.
| Gross Margin | 93.79% |
| Operating Margin | -394.98% |
| Pretax Margin | -410.2% |
| Profit Margin | -425.42% |
| EBITDA Margin | -394.41% |
| EBIT Margin | -394.98% |
| FCF Margin | -370.25% |
